Objectives: The purpose of this study was to assess the effects of intradiscal methylene blue (MB) injection on discogenic low back pain (DLBP). Methods: We conducted an electronic search of the PubMed, Ovid, Ovid MEDLINE and Embase databases using the search terms "low back pain" and "methylene blue"; the search was limited to English language articles from database inception to October 2017. In addition, the reference lists of all included studies were manually searched. Two reviewers independently assessed the quality of the studies, extracted data from the included studies, and analyzed the data. Results: Five studies were included. The results of the metaanalysis indicated that the effects of intradiscal MB injection between preoperation and postoperation on DLBP were statistically significant based on the 3-month visual analog scale (VAS) or numeric rating scale (NRS) (weighted mean difference [WMD] = 3.61; 95% confidence interval [CI]: 2.46 to 4.76; P < 0.05) and Oswestry Disability Index (ODI) (WMD = 24.64, 95% CI: 12.07 to 37.21, P < 0.05), the 6-month VAS or NRS (WMD = 2.95; 95% CI: 1.20 to 4.71; P < 0.05) and ODI (WMD = 23.21, 95% CI: 12.89 to 33.53, P < 0.05), and the 12-month VAS or NRS (WMD = 3.19; 95% CI: 0.99 to 5.40; P < 0.05) and ODI (standard mean difference = 29.51, 95% CI: 20.60 to 38.42, P < 0.05). Conclusions: Intradiscal MB injection can reduce pain severity and improve the ODI score in individuals with discogenic low back pain. Although intradiscal MB injection seems to be a safe and effective treatment for discogenic low back pain, the clinical benefits for patients with discogenic low back pain need to be further appraised in larger samples and more in-depth studies. &
INTRODUCTION
Low back pain has become a common worldwide health problem and a prominent socioeconomic burden on public health. 1, 2 Any pathological change to the lumbar structures may cause low back pain, for example, intervertebral discs, ligaments, fascia, muscles, facet joints, sacroiliac joints, and nerve roots. The internal disruption of intervertebral discs has been thought to be the main cause of low back pain. 3, 4 For instance, it has been reported that up to 42% of cases of low back pain are associated with disrupted intervertebral discs. 5 In addition, intervertebral disc injuries have been reported to be the most common cause (56%) of low back pain caused by motor vehicle accidents. 6 Of note, low back pain originating from intervertebral discs has been shown to be more common in younger patients. 7 As its name implies, discogenic low back pain (DLBP) is defined as pain caused by an internal disturbance in the intervertebral disc. The treatment of DLBP has been a complicated issue. There are many treatments available for DLBP, including injection therapies, thermal annular procedures, interbody fusion, and disc replacement. [8] [9] [10] [11] [12] [13] However, there is considerable controversy over the efficacy of these therapies.
Freemont et al. 14 and Coppes et al. 15 discovered that the pathogenesis of DLBP was associated with nerve growth into the intervertebral disc; when the posterior of the annulus fibrosus was torn as a result of injury or degeneration, the extensive nerve ending extended from the outer layer of the annulus fibrosus into the inner parts of the disc along a torn fissure. Since it was first synthesized in 1876, methylene blue (MB) has been used in many different areas of clinical medicine. 16 For example, MB has been utilized as a neurotropic drug to block nerve conduction or the damage to nerve endings; it has been injected locally to treat many painful ailments and idiopathic pruritus ani [17] [18] [19] [20] ; and recently, it has been used for DLBP. Peng et al. 21 first reported that intradiscal MB injection was an effective and minimally invasive intervention for the treatment of DLBP. Subsequently, Peng et al. 22 verified the efficacy of intradiscal MB injection for DLBP in another doubleblind randomized controlled trial (RCT). However, Schiltenwolf et al. 23 openly questioned the very positive outcome of this RCT. Kim et al. 24 concluded that intradiscal MB injection is an effective short-term treatment but that it may lose its effectiveness over time in their study. In a case series, Gupta et al. 25 found outcomes contrary to the results reported by Peng et al. 22 Nevertheless, Zhang et al. 26 found that intradiscal MB injection might be an effective treatment for DLBP in a short-term clinical observational study.
While the outcomes of the aforementioned studies are controversial, several limitations should be noted, including small sample sizes, inconsistent evaluation criteria, and deficiencies in study design. Therefore, we conducted a large-scale meta-analysis to assess the effects of intradiscal MB injection treatment for DLBP.
METHODS

Search Strategy
This study complied with the recommendations proposed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
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Based on the Cochrane Collaboration guidelines, we conducted an electronic search of the PubMed, Ovid, Ovid MEDLINE, and Embase databases from database inception to October 2017. The search process was conducted as illustrated in Figure 1 . We used the search terms "low back pain" and "methylene blue" in combination with the Boolean operator "AND". In addition, the reference lists of all included studies were manually searched to identify articles that may have been missed in the initial search. This search was limited to English language articles. This study is a metaanalysis that does not require approval by an ethics committee or institutional review board.
Inclusion and Exclusion Criteria
An inclusion criterion was intradiscal MB injection treatment for DLBP patients who were confirmed by the standard pressure-controlled provocative discography. Outcomes included changes in the pain score and Oswestry Disability Index (ODI) from before to after treatment. Exclusion criteria were unavailable or unclear data and duplicate reports.
Study Selection
Once all relevant full-text papers had been gathered, each paper was imported into EndNote (Thomson Reuters ResearchSoft), which is a bibliographic database manager, and duplicates were removed. Two reviewers (LZ.L., SD.Y.) scrutinized the reference lists of each eligible paper for any missed studies. All conflicts were discussed and resolved with a third author (WY.D.).
Data Collection Process and Outcome Measures
Following selection of all relevant articles, two authors (LZ.L., SD.Y.) extracted all data into a preconstructed data table. The following data were extracted: author, year published, age, sample size, pain duration, time of preoperation, and visual analog scale (VAS) or numeric rating scale (NRS) scores and ODI scores of preoperation at follow-up times of 3, 6, and 12 months. For those studies 25, 28, 29 that met the inclusion criteria but data was not readily available in the article, the authors (LZ.L., SD.Y.) tried to contact the researchers via e-mail for raw data.
Assessment of Risk for Bias
Quality assessment of risk for bias was evaluated using the scale from "Assessing the Risk of Bias of Individual Studies in Systematic Reviews of Health Care
Interventions." 30 The scale contains nine questions that refer to selection, performance, attrition, detection, and reporting bias. Risk for bias was independently assessed by two authors (LZ.L., SD.Y.) for each study. Disagreements were discussed and resolved with a third author (WY.D.).
Statistical Analysis
Statistical analysis was performed using Stata/MP 14.0 software (College Station, TX, U.S.A.), and a P value of < 0.05 was considered statistically significant. The outcome measures of the included studies were the 10-cm or 100-mm VAS or the 0-to 10-point NRS for pain assessment, and the 100-point ODI for assessment of specific functions. 31 Pain scores deviating from a linear 0 to 10 or 0 to 100 point scale were transformed to a 10-point scale. 32 Because pain intensity and back function were continuous variables, we calculated the weighted mean differences (WMDs) and the corresponding 95% confidence intervals (CIs) based on the mean values pretreatment and posttreatment. In accordance with the current literature, an improvement in pain intensity of 2 points (0 to 10 points) was considered clinically significant. 33 Heterogeneity of the mean differences across the studies was assessed using the chi-squared test and I 2 statistic. If the results were significant (P < 0.1 or I 2 > 50%), a random-effects model was used to estimate the overall effect sizes, and we conducted subgroup analysis to explore factors related to a decrease in pain scores after intradiscal MB injection. Otherwise, a fixedeffects model was adopted.
RESULTS
Study Characteristics
The initial search identified 284 articles; following removal of duplicates, screening of titles and abstracts identified 19 potential studies. After a detailed review of full text of retrieved studies, eight articles 21, 22, [24] [25] [26] 28, 29, 34 met the inclusion criteria and five 21, 22, 24, 26, 34 ( Figure 1 ) of these were eligible for inclusion in this meta-analysis. The most prevalent reasons for exclusion were invalid reference, incomplete data, and the absence of follow-up. The authors tried to contact the researchers 25, 28, 29 via e-mail for raw data, but failed in the end. The five articles were published from 2007 to 2016, and 121 patients were included. One study 26 was a clinical RCT, but we extracted the data for the intradiscal MB injection group only. Another study 34 included 16 cases, but the follow-up data were incomplete; thus, complete data were extracted for only 8 cases. The characteristics of the five studies are described in Table 1 .
Clinical Outcomes
Decreased Pain Scores (NRS or VAS) After Treatment. Five studies assessed pain scores after treatment using a VAS, a 0 to 10 point NRS, 21, 24, 26, 34 or a 0 to 100 point NRS. 22 The pooled mean differences in pain scores from baseline to follow-up decreased by 3. (Figures 2-4 ). An improvement in pain intensity of 2 points (0 to 10 points) was considered clinically significant. 33 Based on these criteria, the effect of intradiscal MB injection on DBLP was remarkable, with a success rate of at least 50%.
Reduced ODI Score After Treatment. Five studies measured the ODI score (0 to 100) after treatment. 21, 22, 24, 26, 34 The ODI is an assessment scale that is used to measure impairment and quality of life in a patient (ie, how badly the pain has affected the patient's life). It is the gold standard of low back functional outcome measures. The pooled mean differences in ODI score from baseline to follow-up decreased by 24 (Figures 8-12 ). Based on the clinical criteria, 33 the painrelieving effect was remarkable, with a success rate of at least 50% at 6 months; however, the success rate was below 50% at 12 months and the mean ODI score at the 6-month follow-up time was not significantly different from the mean ODI score pretreatment. We also conducted subgroup analysis to explore the sources of heterogeneity in pain scores with respect to patient age (greater than 45 years vs. less than 45 years) and duration of pain prior to the operation (greater than 5 years vs. less than 5 years). The analysis demonstrated that there were no differences in pain scores according to these conditions (Table 2 ).
Safety. No serious complications related to MB intervention were reported in any of the included studies.
Risk for Bias
Quality assessment of risk for bias was evaluated using a scale that contains 9 questions referring to selection, performance, attrition, detection, and reporting bias. Risk for bias values for each study are presented in Table 3 .
DISCUSSION
Low back pain is a common health problem worldwide and has a significant socioeconomic burden on public health.
1,2 It has been reported that up to 42% of cases of low back pain are associated with disruption of intervertebral discs. 5 While the exact pathogenesis of DLBP is very complicated, a widely accepted hypothesis is that the pain is caused by nociceptive nerves growing deeply into the nucleus pulposus along the torn fissure in the posterior part of the annulus fibrosis. 14, 15 One possible mechanism by which intradiscal MB injection relieves pain in cases of DLBP is via denervation of the small nociceptive fibers that grow into the inner layer of the annulus fibrosis or nucleus pulposus. Another possible mechanism is that MB may alleviate inflammatory processes underlying pain by directly inhibiting synthesis of nitric oxide, which plays an important role in the inflammatory processes of intervertebral disc degeneration and DLBP.
14,35 In this study, we retrieved eight articles about intradiscal MB injection that met the inclusion criteria, each of which had different clinical outcome. Peng et al. 21 in 2007 conducted a trial of intradiscal MB injection for the treatment of DLBP, in which they examined the effect of intradiscal MB injection in 24 patients with intractable DBLP for whom conservative treatment had been minimally effective. They found a remarkable improvement in pain (defined as a minimum of a 2-point reduction in pain intensity on the VAS compared with pain intensity pretreatment) in 87% of the patients. Based on the VAS and ODI, there was no difference in pain intensity between 3 and 12 months (or more) postoperation for all the patients. In 2010, Peng et al. 22 demonstrated the efficacy and safety of intradiscal MB injection in 72 patients with DLBP through a double-blind randomized trial. In this study, patients who received intradiscal MB injections showed a 52.5-point reduction in mean NRS score and a 35.6-point reduction in ODI score. The overall success rate following treatment was 89%, with 47% of the patients reporting complete relief of pain at the 6-month followup and a 91.6% satisfaction rate at 24 months after treatment. In a similar study in 2012, Kim et al. 24 reported that the average VAS score decreased significantly from 5.1 at baseline to 3.2 at 3 months after intradiscal MB injection and that the ODI score decreased significantly from 38.0 at baseline to 10.2 at 3 months after intradiscal MB injection in patients with DBLP; however, at the 12-month follow-up time, the mean VAS score dropped to 4.5 (not significantly different from the pretreatment scores), and the success rate decreased from 55% at 3 months to 20% at 12 months after treatment. Based on these findings, the authors concluded that intradiscal MB injection is an effective short-term treatment but that it may lose its effectiveness over time. In the same year, Gupta et al. 25 reported a clinical trial with a cohort of eight patients with mental health issues, and their results revealed a success rate of only 13%, in contrast to the outcomes reported by Peng et al. 21, 22 In 2014, Levi et al. 34 defined success as improvement of at least 30% on the VAS accompanied by improvement of at least 30% on the ODI, and they found that the success rate was only 19%, 21%, and 25% for the 1-, 2-, and 6-month follow-up times, respectively. Kallewaard et al. 28 found that 40% of the patients who responded to this treatment according to the VAS and ODI improved by at least 30%. However, in a recent study by Zhang et al. 26 (2016), which defined successful outcome as at least 50% improvement on the ODI and 2-point reduction in NRS scores, the clinical success rates were 81%, 75%, and 63% at the 1-, 3-, and 6-month follow-up times after treatment, respectively. At 12 months after treatment, only 54% of the patients showed a successful clinical outcome; therefore, the efficacy of MB injection for DLBP may not persist. Another triple-blind, randomized placebo-controlled trial conducted by Farrokhi et al. 29 examined the effects of MB injection on postoperative low back pain and functional outcomes after lumbar open discectomy and showed that the group of MB-treated patients had significantly less low back pain than the control group at 24 hours and 3 months after surgery, consistent with the findings of Peng et al. 21, 22 Thus, we conducted the present meta-analysis including all published studies to precisely estimate the effects of intradiscal MB injection.
No serious complications related to MB intervention were reported in the studies included in this review. However, some serious complications related to intervertebral disc injection were often reported in the literature, such as discitis (infection or inflammatory), [36] [37] [38] [39] disc herniation, 40 and nerve or vascular injury. [41] [42] [43] These complications should be taken into account in the procedure of intradiscal treatment.
The overall results of this meta-analysis were positive, although the subgroup analyses were different. The pain relieving effect was remarkable, with a success rate of at least 50% at 6 months; however, the success rate was below 50% at 12 months, and the mean ODI score at the 6-month follow-up time was not significantly different from the mean pretreatment ODI score. According to the subgroup analysis data, the long-term effect of intradiscal MB injection was not good.
Our study has several limitations. Although we conducted a comprehensive search in four databases, only five studies were included in this meta-analysis. Three studies 25, 28, 29 met the inclusion criteria, but data were not readily available in the article; we tried to contact the researchers via e-mail for raw data, but failed in the end. The small number of studies and patients included limit our confidence in the findings. A considerable degree of heterogeneity was still observed among the included trials despite the subgroup analysis. This might be due to differences in patient characteristics, such as the cause of pain, the pain severity at baseline, and the treatment protocols, or otherwise unknown biases in those studies. In addition, the 12-month follow-up period was not long enough. The clinical benefits of intradiscal MB injection for patients with DLBP require further investigation and should be further evaluated in large cohorts through multicenter studies and RCTs.
CONCLUSION
In summary, the findings of this meta-analysis suggest that intradiscal MB injection can reduce the pain severity and improve the ODI scores of patients with DLBP. Although intradiscal MB injection seems to be a safe and effective treatment for DLBP, its clinical benefits for patients with DLBP must be further studied in larger cohorts and in greater detail. On the basis of the literature to date, the precise success rate remains unclear. At present, intradiscal MB injection is not a standard treatment for discogenic pain. However, for patients who have responded poorly to traditional treatments, intradiscal MB injection could be a promising treatment.
